Key result
Cardea SOLO provides readable ECGs for up to 5 days in horses, correlating well with Televet.
Why the study?
Arrhythmias cause poor performance and sudden death in horses, and long-term ECG monitoring can detect transient arrhythmias, but the performance of the 7-day Cardea SOLO patch had not been validated against the gold-standard Televet device.
Does the Cardea SOLO wearable ECG patch provide valid continuous monitoring compared to the Televet device in healthy horses?
Does the Cardea SOLO wearable ECG patch provide valid continuous monitoring compared to the Televet device in healthy horses?
The Cardea SOLO wearable ECG patch is a viable option for up to 5-day continuous ECG monitoring in horses, showing good correlation with standard devices despite a higher rate of false-positive premature complexes.
Answers are grounded in this paper and cite their sources.
May enable 7-day equine ECG monitoring; leaves open prospective validation against gold-standard devices.
Background Arrhythmias can cause poor performance and sudden death in horses. Long‐term (>24 h) electrocardiogram (ECG) monitoring has been used to identify arrhythmias in humans and is superior to short‐term monitoring for transient arrhythmia detection. Televet is the current equine gold‐standard ECG device. The Cardea SOLO™ (CS) is a single‐use monitor with automated ECG analysis software allowing ECG monitoring for 7 days. Objective Our objective was to validate the performance of the CS compared to the Televet. Study Design Method validation. Methods ECGs were performed on 12 healthy horses simultaneously using both devices for 24 h on day 1 and day 7, with the CS left in place for all 7 days. Each ECG was manually reviewed to identify correctly and incorrectly classified complexes. Generalised linear models were used to identify differences in the arrhythmia classifications and the proportion of unusable minutes. For eight horses, Bland–Altman analysis and correlation were performed to test for agreement between the two devices for standard ECG measurements. Results The CS recorded and analysed ECGs for up to 7‐days without adverse effects in all horses. The proportion of readable ECG decreased markedly after day 5 and CS identified more false positive premature complexes than Televet. The correlation between devices for ECG measurements ranged from good to excellent. Main Limitations The major limitations of our study are the relatively small sample size ( n = 12) and the challenge in starting both devices at the same time led to only eight horses being included in the device measurement comparisons. The CS is a single lead ECG which may have led to incorrectly classified premature depolarisation types on manual inspection. Conclusions This study demonstrates the CS utility for 5‐day ECG monitoring and screening for arrhythmias in healthy horses. CS utility for the detection of pathological arrhythmias requires further investigation.
No takes yet. Share an insight, caveat, or question.
Dias et al. (2026) studied Healthy horses (n=12). Cardea SOLO™ (CS) vs. Televet was evaluated on Agreement between devices for standard ECG measurements and arrhythmia classifications. The Cardea SOLO device provided readable ECG monitoring for up to 5 days in healthy horses, demonstrating good to excellent correlation with the Televet device for standard ECG measurements.
Synapse has enriched 10 related papers. Consider them for comparative context: